Elevance Health: A Quality Underpriced Stock Returning To Health
Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration.
Elevance Health Stock Falls As Anthem Faces Backlash Over Anesthesia Policy, Announces Reversal
When Anthem Blue Cross Blue Shield said it will no longer pay for anesthesia care if the surgery or procedure exceeds an arbitrary time limit, parent company Elevance Health Inc ELV faced backlash and reneged on the policy change.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
What's Behind The 15% Fall For Elevance Health Stock?
Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus estimates. The company reported revenue of $44.7 billion and adjusted earnings of $8.37 per share, compared to the street estimates of $43.5 billion and $9.66, respectively.
Elevance Health Stock: Looking Beyond Near-Term Issues, I'm A Buyer
Elevance Health's Q3 2024 results were disappointing with a significant increase in the benefit expense ratio and lowered earnings expectations for the full year. I take a close look at ELV's exposure to government plans and their profitability. I explain why I view Elevance stock as favorably valued even under very conservative near and long-term growth assumptions.
These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings
Elevance Health Inc. ELV reported weaker-than-expected earnings for its third quarter on Thursday.
S&P 500 Gains and Losses Today: Health Insurers Slide as Elevance Cites Medicaid Declines
Major U.S. equities indexes were mixed as earnings results from Taiwan Semiconductor Manufacturing (TSM) helped revitalize optimism around artificial intelligence (AI) and September retail sales data came in ahead of forecasts.
Elevance Health: A Bad Q3 Was Almost Inevitable Given Industry Headwinds
Elevance Health's Q3 earnings report led to a 14% stock price drop due to increased benefit expense ratio and declining EPS. The health insurance industry faces challenges, particularly in Medicare Advantage and Medicaid, affecting profitability and causing industry-wide share price declines. Elevance's management expects revenue growth in 2025 but acknowledges ongoing profitability issues, suggesting a cautious outlook for the near term.
Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations
ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.
Why Is Elevance Health Stock Trading Lower On Thursday?
Elevance Health Inc. ELV reported on Thursday third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
Elevance Health earnings: Higher medical costs weigh on profits
CNBC's Bertha Coombs reports on Elevance Health's quarterly earnings results.
Elevance Health Stock Plunges on Profit Hit From Fall in Medicaid Memberships
Elevance Health (ELV) shares cratered Thursday after the insurer posted a lower-than-expected profit and slashed its outlook on falling Medicaid enrollments.
